search

Prelude Therapeutics Inc (PRLD)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Prelude Wins FDA Clearance to Move Breast Cancer Drug to Trial
Sep 17, 2026

Prelude Wins FDA Clearance to Move Breast Cancer Drug to Trial

Prelude Therapeutics Inc. has received FDA clearance to initiate a Phase 1 trial for PRT13722, an experimental KAT6A-targeting breast cancer drug. The trial will investigate the drug as a monotherapy and in combination with other treatments for advanced or metastatic hormone receptor-positive, HER2-negative breast cancer. Prelude's approach focuses on selectively degrading KAT6A to improve efficacy and safety compared to dual KAT6A/B inhibitors.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish